The Rapamycin Longevity Lab is a cutting-edge research organization focused on advancing the use of mTOR inhibitors as the core component in longevity combinational therapies. The lab is founded by Krister Kauppi and the aim is to develop combinational therapies that not only slow down aging but also eventually solve aging altogether. By leveraging mTOR inhibitor’s potential and combining it with other interventions, the lab seeks to extend lifespan and improve healthspan in both animal models and humans.
Krister Kauppi is the founder of the Rapamycin Longevity Lab. His vision is to take mTOR inhibition, particularly through rapamycin, to the next level by integrating it into complex longevity cocktails. Kauppi’s approach focuses on combination therapies, which he believes will be key to addressing aging at its core, rather than relying on any single treatment.
The Rapamycin Longevity Lab is building expertise in engineering longevity cocktails — therapies that combine mTOR inhibitor's with other compounds to achieve optimal effects in lifespan extension. The lab is positioning itself as a leader in the field of combinatory therapies, aiming to fill a gap in the current aging research landscape, where few actors focus on such multifaceted approaches. Through partnerships with companies like Ora Biomedical, Rapamycin Longevity Lab efficiently screens and tests new combinations of therapies, with a long-term goal of translating this research into human clinical trials.
Apply to become a Certified Vitalist Organization and align with others dedicated to this mission
CERTIFICATION APPLICATION
